Emerging Technology — Patient Conversation

The Organ Is Only as Good as the Clock It Beat.

Every organ that travels from donor to recipient is racing a clock the moment blood flow stops. Biological Hemoglobin Oxygen Carrier (BHOC) research is one of the rare efforts asking whether that clock can be met with oxygen instead of only cold — and almost no patient or care partner has ever heard of it.

Who Is Building It
Company Spotlight

BHOC Therapeutics

Building the next chapter of oxygen-delivery science.

BHOC Therapeutics develops Biological Hemoglobin Oxygen Carriers (BHOC): a cell-free form of hemoglobin designed to carry oxygen and release it where tissue needs it. Because it has no red-cell membrane and no blood-group antigens, it is designed to be compatible with all blood types. The company calls its approach Precision Oxygen Therapeutics, which means oxygen delivery that is controlled and predictable, down to the tissue and the cell.

The Technology

  • Cell-free hemoglobin, with no red-cell antigens
  • Engineered oxygen affinity for controlled loading and release
  • Long shelf life targeted, for room-temperature handling
  • Robust and portable for practical transport

What They Aim For

A complementary oxygen-delivery bridge, not a replacement for blood. Their research areas include organ transplantation, severe anemia, surgery and blood loss, cardiac and ischemic emergencies, sickle cell disease, emergency and remote care, and veterinary medicine.

Mission & Values

  • Evidence before claims: every claim is linked to its scientific, clinical or regulatory source
  • Honest framing: they don't call it “artificial blood”
  • Life at every scale: protect life, preserve species, safeguard biodiversity

“One Oxygen. Every Species. One Living Planet.”

Visit BHOC Therapeutics at bhoctherapeutics.com →

Opens bhoctherapeutics.com in a new tab. BHOC Therapeutics notes that these are areas of research and development, not approved therapeutic claims.

Transplantation Evidence Hub · bhoctherapeutics.com

Oxygen Delivery Across the Graft Journey

Transplantation oxygen therapeutics. Evidence in context.

Within bhoctherapeutics.com, BHOC Therapeutics maintains a Transplantation Evidence Hub: a source-linked map of 64 publications on oxygen carriers in organ transplantation, spanning liver, kidney, heart, lung, limb and composite tissue, and cross-organ perfusion and preservation research. Its starting principle is plain — start with the graft — and its question is whether controlled oxygen delivery could support a donated organ at the moments it is most vulnerable.

Why it matters here: the first intervention point the hub maps is preservation — the cold ischemia window this foundation is named for, when an organ waits, cooled and without blood flow, for the body that will receive it.

  1. PreservationThe organ held between donor and recipient
  2. Machine perfusionOxygenated perfusion outside the body
  3. Viability assessmentJudging whether the organ can be used
  4. ReperfusionBlood flow restored in the recipient

Two Evidence Layers

Historical oxygen-carrier studies, such as those with Hemopure, are kept separate from wider transplantation research that could inform future BHOC work, so neither borrows credibility from the other.

Follow the Work

Every record is traced to its original publication, so readers can follow each finding to its origin rather than take a summary on faith.

Their Standard

  • Listing a study does not establish efficacy or approval
  • Related transplant studies are not BHOC efficacy evidence
  • Educational information, not clinical advice
Explore the Transplantation Evidence Hub at bhoctherapeutics.com →

Opens bhoctherapeutics.com in a new tab. BHOC Therapeutics states that including a publication does not establish efficacy, regulatory approval or a clinical recommendation.

What It Actually Is

Not a blood transfusion. Not a replacement for blood. A precise way to deliver oxygen where tissue is running short.

Cold ischemia — the time an organ spends without blood flow between recovery and transplant — is the single most damaging window in the entire transplant process, and it's also the namesake of this foundation for a reason. The longer that window stretches, the more cellular damage accumulates before the organ is ever reconnected to a body.

A BHOC — Biological Hemoglobin Oxygen Carrier — is hemoglobin, the molecule red cells use to carry oxygen, working outside the red cell. With no cell membrane it carries no blood-group antigens, so it is designed to be compatible with all blood types, and its oxygen affinity is engineered so it loads oxygen and releases it where the surrounding tissue needs it. BHOC Therapeutics calls the framework Precision Oxygen Therapeutics, built on a sagacious premise: blood is a system; oxygen delivery is a function. The question is not whether BHOC can replace blood — it is not designed to — but where, when, how much and how effectively oxygen reaches the cells that depend on it.

In transplantation, BHOC Therapeutics maps that question across four points: preservation, machine perfusion, viability assessment and reperfusion. Today's standard preservation relies largely on cold to slow an organ's metabolism; oxygen-delivery research asks whether some of the damage cold can only delay might be prevented altogether.

Cold storage slows the damage. Controlled oxygen delivery asks whether some of it never has to happen.

Why Patients Never Hear About This

It lives in surgical journals and industry panels — never in the room with the patient.

This is not a secret. It's published, presented, and discussed — but almost exclusively among transplant surgeons, organ preservation researchers, and the companies developing the technology. It essentially never makes it into a conversation with the person actually waiting for an organ, or the care partner who's about to spend the next year managing their recovery.

That gap matters for a simple reason: technology that could shorten viable preservation windows, expand the geographic range organs can travel, and reduce delayed graft function isn't just a surgical curiosity. It's directly relevant to whether a specific patient in a specific region gets offered a specific organ at all. Patients deserve to understand what's being worked on to solve the problem that keeps them waiting — not just be told the waitlist is long.

For Patients

What it could mean

Organs preserved longer and better could mean a wider pool of viable offers reaching people who are currently ruled out by distance or timing alone.

For Care Partners

Why it's worth tracking

Delayed graft function — a major driver of a harder first weeks post-transplant — is closely tied to how much damage an organ sustained before transplant. Better preservation is a care partner's problem too.

For the System

Why it's stuck in the lab

Novel preservation technology faces a slow, expensive, heavily regulated path to clinical adoption — and no organized patient constituency is currently pushing for it to move faster.

Where CIF Fits

We're not the company building it. We're the ones making sure patients know it exists.

Cold Ischemia Foundation works directly with BHOC Therapeutics — not to promote a product, but to translate what this technology is, what it isn't, and why it deserves a place in the conversation patients and care partners are having about the future of transplant medicine. That means plain-language explanation instead of a surgical journal abstract, and outreach to the regulatory and clinical bodies who decide whether emerging preservation technology reaches the people waiting for it.

This is early-stage, evolving technology. It is not yet standard of care, and no patient should expect it to change their current transplant timeline. The goal here is awareness and informed conversation — not premature promises.

If preservation technology is going to move faster from lab to standard practice, it will be because the people who actually have something at stake — patients, care partners, living donors — understood it well enough to ask their transplant centers about it. That's the conversation this page exists to start.

The People Behind BHOC

The scientists and builders CIF works alongside.

Biological Hemoglobin Oxygen Carrier science did not appear overnight. It rests on four decades of purification chemistry, regulatory battles and evidence-building by a small circle of people — the same people Cold Ischemia Foundation collaborates with to bring this work into the open.

Archil Jaliashvili
Architect of BHOC

Archil Jaliashvili

BHOC Therapeutics

A biotechnology and healthcare executive with more than 20 years of experience who leads the scientific and strategic development of BHOC Therapeutics, and who defined BHOC around controlled, tissue-level oxygen delivery.

  • Co-author of the 2026 preprint establishing the BHOC and Precision Oxygen Therapeutics framework
  • Built the BHOC Scientific Evidence Hub and BHOC Veterinary resources
  • Keeps human, veterinary and regulatory evidence source-linked and separate
ORCID 0009-0006-4712-4942
Carl W. Rausch
Scientific Pioneer

Carl W. Rausch

Co-founder & former Chairman and CEO, Biopure

An MIT-trained chemical engineer who spearheaded the patented purification and molecular cross-linking techniques behind the first hemoglobin oxygen therapeutics ever approved — the technical bedrock BHOC builds on.

  • Co-founded Biopure in 1984 and led development of Oxyglobin and Hemopure
  • Oxyglobin became the first FDA-approved veterinary oxygen therapeutic (1998); Hemopure won human approval in South Africa (2001)
  • Holds 11 patents; co-author of the 2026 BHOC framework preprint
MS Chemical Engineering, MIT